Literature DB >> 30127039

Hepatic sarcoidosis.

Toshiyuki Watanabe1, Satoshi Jodo2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30127039      PMCID： PMC6102111          DOI： 10.1503/cmaj.180276

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1.  The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis.

Authors:  Dragana Sobic-Saranovic; Isidora Grozdic; Jelica Videnovic-Ivanov; Violeta Vucinic-Mihailovic; Vera Artiko; Djordjije Saranovic; Aleksandra Djuric-Stefanovic; Dragan Masulovic; Strahinja Odalovic; Aleksandra Ilic-Dudvarski; Spasoje Popevic; Smiljana Pavlovic; Vladimir Obradovic
Journal:  J Nucl Med       Date:  2012-08-09       Impact factor: 10.057

2.  Clinical Characteristics and Outcome of Hepatic Sarcoidosis: A Population-Based Study 1976-2013.

Authors:  Patompong Ungprasert; Cynthia S Crowson; Douglas A Simonetto; Eric L Matteson
Journal:  Am J Gastroenterol       Date:  2017-09-05       Impact factor: 10.864

3.  Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients.

Authors:  Yvan Jamilloux; Fleur Cohen-Aubart; Catherine Chapelon-Abric; Delphine Maucort-Boulch; Alicia Marquet; Laurent Pérard; Laurence Bouillet; Alban Deroux; Sébastien Abad; Philip Bielefeld; Diane Bouvry; Marc André; Nicolas Noel; Boris Bienvenu; Alice Proux; Sandra Vukusic; Bahram Bodaghi; Françoise Sarrot-Reynauld; Jean Iwaz; Zahir Amoura; Christiane Broussolle; Patrice Cacoub; David Saadoun; Dominique Valeyre; Pascal Sève
Journal:  Semin Arthritis Rheum       Date:  2017-03-08       Impact factor: 5.532
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.